 Precision BioSciences, Inc. DTIL, a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus HBV program developed under its 2018 collaboration agreement with Gilead Sciences. This was a highly productive and well-aligned collaboration, and we deeply value the opportunity to advance our ARCUS genome editing technology and a potential cure for HBV alongside a global leader in infectious disease, commented Derek Jantz, Ph.D., Chief Scientific Officer, Precision BioSciences. 